Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Science

• Publication date

  2000-04-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/SCIENCE.288.5466.669PMID 10784449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.

  2000cited by this paper
• Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer.

  2000cited by this paper
• Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach.

  1999cited by this paper
• Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

  1999cited by this paper
• Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells.

  1998cited by this paper
• T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates

  1998cited by this paper
• Natural and engineered disorders of lymphocyte development.

  1998cited by this paper
• A new chance for SCID gene therapy

  1998cited by this paper
• gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures.

  1998cited by this paper
• γc Gene Transfer in the Presence of Stem Cell Factor, FLT-3L, Interleukin-7 (IL-7), IL-1, and IL-15 Cytokines Restores T-Cell Differentiation From γc(−) X-Linked Severe Combined Immunodeficiency Hematopoietic Progenitor Cells in Murine Fetal Thymic Organ Cultures

  1998cited by this paper
• Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes.

  1998cited by this paper
• Identification of clonogenic common lymphoid progenitors in mouse bone marrow.

  1997cited by this paper
• Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells.

  1996cited by this paper
• The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID.

  1996cited by this paper
• Retroviral-mediated gene correction for X-linked severe combined immunodeficiency.

  1996cited by this paper
• The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling.

  1996cited by this paper
• Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells

  1996cited by this paper
• Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene.

  1996cited by this paper
• gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function.

  1996cited by this paper
• Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.

  1996cited by this paper
• Bone marrow gene transfer in three patients with adenosine deaminase deficiency.

  1996cited by this paper
• Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients

  1995cited by this paper
• Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.

  1995cited by this paper
• Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency

  1995cited by this paper
• INTERLEUKIN-2 RECEPTOR γ CHAIN MUTATION RESULTS IN X-LINKED SEVERE COMBINED IMMUNODEFICIENCY IN HUMANS

  1994cited by this paper
• The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments.

  1993cited by this paper

• Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology

  2026cites this paper
• Limited bone marrow chimerism impairs cell competition in the thymus and causes leukemia

  2026cites this paper
• CRISPR-Cas9–based gene editing as a proof-of-concept approach in an inborn error of immunity caused by a DCLRE1C variant

  2026cites this paper
• Monitoring biological effects of somatic cell genome editing.

  2026cites this paper
• Demystifying Gene-Based Therapies in Pediatric Health Care

  2026cites this paper
• Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells

  2026cites this paper
• Viral vector research in human gene therapy: basic principles, alternative evaluation models, and clinical applications.

  2026cites this paper
• Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update

  2025cites this paper
• Exploring enterovirus pathogenesis and cancer therapy potential through reverse genetics

  2025cites this paper
• Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness

  2025cites this paper
• Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy

  2025cites this paper
• Current approaches in CRISPR-Cas system for metabolic disorder.

  2025cites this paper
• Ex vivo Modification of Hematopoietic Stem and Progenitor Cells for Gene Therapy.

  2025cites this paper
• Human immunity

  2025cites this paper
• Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

  2025cites this paper
• Gene therapy for inborn errors of immunity: past progress, current status and future directions

  2025cites this paper
• Optimizing Hydrophobic Chain Length in Cardanol‐Based Quaternary Ammonium Compounds Enhances Gene Delivery Efficiency

  2025cites this paper
• Unlocking the potential: advancements and applications of gene therapy in severe disorders

  2025cites this paper
• Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects.

  2025cites this paper
• Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells

  2025cites this paper
• mRNA and gene therapy for diabetes: The next-generation treatment frontiers.

  2025cites this paper
• Cancer gene therapy: historical perspectives, current applications, and future directions

  2025cites this paper
• Targeting immune heterogeneity in liver metastases through in vivo genetic engineering.

  2025cites this paper
• MicroRNA nanoformulation: a promising approach to anti-tumour activity

  2025cites this paper
• Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer

  2025cites this paper
• Gene therapy in neovascular age related macular degeneration: an update

  2025cites this paper
• Advancing ex vivo gene therapy: the role of lentiviral vectors and organizational collaboration.

  2025cites this paper
• Unlocking the Puzzle of Mammalian Transfection: The Role of the RNA-sensing-Mediated Interferon Response in the Cellular Defense Against Foreign DNA Intrusion

  2025cites this paper
• Application of Gene Therapy to Oral Diseases

  2025cites this paper
• Somatic mutations in autoinflammatory and autoimmune disease

  2024cites this paper
• Cutting-Edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease.

  2024cites this paper
• Preclinical ex vivo IL2RG gene therapy using autologous hematopoietic stem cells as an effective and safe treatment for X-linked severe combined immunodeficiency disease

  2024cites this paper
• Gene Therapy on Cancer Diseases

  2024cites this paper
• A Brief Review on Gene Therapy

  2024influential citation
• In Situ Polymerization for Manufacture of Multifunctional Delivery Systems for Transcellular Delivery of Nucleic Acids.

  2024cites this paper
• Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome.

  2024cites this paper
• Adeno-Associated Virus Vectors—a Target of Cellular and Humoral Immunity—are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies

  2024cites this paper
• Gene therapy clinical trials worldwide to 2023—an update

  2024cites this paper
• AUTOLOGOUS STEM CELL-BASED GENE THERAPY OFFERS AN INNOVATIVE SOLUTION FOR TREATING INHERITED BLOOD CELLS DISORDERS

  2024cites this paper
• Alpharetroviral Vector–Mediated Gene Therapy for IL7RA-Deficient Severe Combined Immunodeficiency

  2024cites this paper
• Utilizing epigenetic regulators to improve HSC-based lentiviral gene therapy

  2024cites this paper
• Bioorthogonal Activation of RCA-Based Amplifiable DNAzymes in Bimetallic NMOF for Precise Gene/Chemo-Dynamic Combination Therapy

  2024cites this paper
• Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

  2024cites this paper
• Genetic Screening—Emerging Issues

  2024cites this paper
• Targeted gene delivery systems for T-cell engineering

  2024cites this paper
• Gene Therapy Strategies for RAG1 Deficiency: Challenges and Breakthroughs.

  2024cites this paper
• In Utero Gene Therapy and its Application in Genetic Hearing Loss

  2024cites this paper
• Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications

  2024cites this paper
• Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy.

  2023cites this paper
• A new era of gene and cell therapy for cancer: a narrative review

  2023cites this paper
• Immundefekte – neue Entwicklungen, die Kinderärzte kennen sollten

  2023cites this paper
• Déficits immunitaires primitifs

  2023cites this paper
• Role of gene therapy in treatment of cancer for craniofacial regeneration—current molecular strategies, future perspectives, and challenges: a narrative review

  2023influential citation
• Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactors

  2023cites this paper
• Personalized hematopoietic stem cell transplantation for inborn errors of immunity

  2023cites this paper
• Gene therapy for inborn errors of immunity.

  2023cites this paper
• Correcting inborn errors of immunity: From viral mediated gene addition to gene editing

  2023cites this paper
• Nonviral Ex Vivo Genome Editing in Mouse Bona Fide Hematopoietic Stem Cells with CRISPR/Cas9.

  2023cites this paper
• Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

  2023cites this paper
• Protein-mediated genome folding allosterically enhances site-specific integration of foreign DNA into CRISPRs

  2023cites this paper
• The First Three Decades of Gene Therapy: An Instant Update

  2023cites this paper
• Pseudotyped Viruses for Retroviruses.

  2023cites this paper
• A Review of Different Types of Liposomes and Their Advancements as a Form of Gene Therapy Treatment for Breast Cancer

  2023cites this paper
• Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

  2023cites this paper
• CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells

  2023cites this paper
• Clustered regularly interspaced short palindromic repeats/Cas9-mediated gene editing. A promising strategy in hematological disorders.

  2023cites this paper
• Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

  2023cites this paper
• Developing non-viral or viral vectors for efficient and targeted delivery of genetic material, such as DNA or RNA, for gene therapy applications

  2023cites this paper
• Lecznicze produkty terapii zaawansowanej jako wytwory innowacyjnych biotechnologii

  2023cites this paper
• Severe Combined Immunodeficiency (SCID) and Its New Treatment Modalities

  2023cites this paper
• Successes and challenges in clinical gene therapy

  2023cites this paper
• Genome Editing Technologies and Application in Medicine: Discoveries, Challenges, and Prospects

  2023cites this paper
• Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors

  2023cites this paper
• Viral Vectors in Gene Replacement Therapy

  2023cites this paper
• Structure reveals why genome folding is necessary for site-specific integration of foreign DNA into CRISPR arrays

  2023cites this paper
• History of Gene Therapy

  2023cites this paper
• THE JEREMIAH METZGER LECTURE: TURNING GENES INTO MEDICINES: HIGHLIGHTS AND HURDLES IN THE DEVELOPMENT OF GENE THERAPY FOR GENETIC DISEASE.

  2023cites this paper
• Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases

  2023cites this paper
• Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD.

  2023cites this paper
• Fetal gene therapy

  2023cites this paper
• Viral vectors engineered for gene therapy.

  2023cites this paper
• A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice

  2023cites this paper
• Biotechnological Advances in Gene Therapy of Hematopoietic Stem Cells: Systematic Review and Meta-Analysis

  2023influential citation
• Progress of Endogenous and Exogenous Nanoparticles for Cancer Therapy and Diagnostics

  2023cites this paper
• Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.

  2023cites this paper
• Transcriptomic Analysis of Insulin-Secreting Murine Hepatocytes Transduced with an Integrating Adeno-Associated Viral Vector

  2023cites this paper
• Advances in gene therapy for inborn errors of immunity

  2023cites this paper
• Gene therapy for inborn error of immunity - current status and future perspectives.

  2022cites this paper
• Current strategies employed in the manipulation of gene expression for clinical purposes

  2022cites this paper
• Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs

  2022cites this paper
• Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology

  2022cites this paper
• Gene Therapy Cargos Based on Viral Vector Delivery.

  2022cites this paper
• Gene therapy for inborn errors of immunity: past, present and future

  2022cites this paper
• miRNA Pathway Alteration in Response to Non-Coding RNA Delivery in Viral Vector-Based Gene Therapy

  2022cites this paper
• Delivering gene therapy for mucopolysaccharide diseases

  2022cites this paper
• A great disturbance in the force: IL-2 receptor defects disrupt immune homeostasis

  2022cites this paper
• The discovery and development of RNA-based therapies for treatment of HIV-1 infection

  2022cites this paper
• Genome Editing in Translational Medicine: An Inventory.

  2022cites this paper
• Preparation of PEI‐modified nanoparticles by dopamine self‐polymerization for efficient DNA delivery

  2022cites this paper
• Gene therapy approaches for equine osteoarthritis

  2022cites this paper